Paris, France, October 4, 2016—BIOMILLENIA announces its collaboration with the life science business of Merck on the development of an improved enzyme used in vaccine production processes.
Following a successful technology evaluation project employing BIOMILLENIA’s proprietary droplet-based microfluidic cell culture and screening technology platform, BIOMILLENIA and Merck will collaborate on the development of a market-leading enzyme in Merck’s portfolio of industry-leading enzyme solutions.
“The BIOMILLENIA 300X platform combines magnitudes higher throughput and speed for culture and screening of microbe variants or enzyme variants over traditional screening methods,” said Dr. Dirk Löffert, President of BIOMILLENIA. “The collobaration with MERCK is yet another example for our ambition to become a leading complete solution provider to our partners for the development of improved enzyme versions or production strains. Our unprecedented capability in culturing and screening millions of strain or enzyme variants in parallel in very short development cycles has been proven to become a key differentiator for the development of GMO and non-GMO based products.”
Terms of the collaboration were not disclosed.
BIOMILLENIA is a leading company for the development of production strains and enzymes. Its unique technology platform delivers novel bacterial, fungal or yeast strain properties and enzymes for the manufacture of chemicals and natural products at throughputs and speeds several orders of magnitudes higher than with traditional methods. BIOMILLENIA “Unlocks Nature’s Potential” for cost-competitive and sustainably manufactured novel biology-based products for a better life.
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries. Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.